Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers

There is no fulltext present in this item.

Title:	Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
Author(s):	Zaaijer, L.H.; Doorn, H.C. van; Mourits, M.J.; Beurden, M. van; Hullu, J.A. de ; Adank, M.A.; Lonkhuijzen, L.R. van; Vasen, H.F.; Slangen, B.F.; Gaarenstroom, K.N.; Zweemer, R.P.; Vencken, P.M.; Seynaeve, C.; Kriege, M.
Publication year:	2016
Source:	British Journal of Cancer, vol. 115, iss. 10, (2016), pp. 1174-1178
ISSN:	0007-0920
DOI:	https://doi.org/10.1038/bjc.2016.333
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/171109
Display more details
Subject:	Radboudumc 17: Women's cancers RIHS: Radboud Institute for Health Sciences
Organization:	Gynaecology
Journal title:	British Journal of Cancer
Volume:	vol. 115
Issue:	iss. 10
Page start:	p. 1174
Page end:	p. 1178
Abstract:	BACKGROUND: It is unknown whether a history of breast cancer (BC) affects the outcome of BRCA1/2-associated epithelial ovarian cancer (EOC). This was investigated in the current analysis. METHODS: We included 386 BRCA1/2-associated EOC patients diagnosed between 1980 and 2015. Progression-free survival (PFS), progression-free interval (PFI), overall survival (OS) and ovarian cancer-specific survival (OCSS) were compared between EOC patients with and without previous BC. RESULTS: BRCA-associated EOC patients with, vs without, a BC history had a significantly worse PFS and PFI (multivariate hazard ratio (HRmult) 1.47; 95% confidence interval (CI) 1.03-2.08 and HRmult 1.43; 95% CI 1.01-2.03), and a non-significantly worse OS (HRmult 1.15; 95% CI 0.84-1.57) and OCSS (HRmult 1.18; 95% CI 0.85-1.62). Ovarian cancer-specific survival was significantly worse for the subgroup treated with adjuvant chemotherapy for BC (HRmult 1.99; 95% CI 1.21-3.31). CONCLUSIONS: Our results suggest that BRCA1/2-associated EOC patients with a previous BC have a worse outcome than EOC patients without BC, especially when treated with adjuvant chemotherapy.